Anti-viral treatment and cancer control
Journal
Recent Results in Cancer Research
Journal Volume
193
Pages
269-290
Date Issued
2014
Author(s)
Abstract
Hepatitis B virus (HBV), hepatitis C virus (HCV), human papillomavirus (HPV), and Epstein-Barr virus (EBV) contribute to about 10-15 % global burden of human cancers. Conventional chemotherapy or molecular target therapies have been used to treat virus-associated cancers. However, a more proactive approach would be the use of antiviral treatment to suppress or eliminate viral infections to prevent the occurrence of cancer in the first place. Antiviral treatments against chronic HBV and HCV infections have achieved this goal, with significant reduction in the incidence of hepatocellular carcinoma in treated patients. Antiviral treatments for EBV, Kaposi's sarcoma-associated herpesvirus (KSHV), and human T-cell lymphotropic virus type 1 (HTLV-1) had limited success in treating refractory EBV-associated lymphoma and post-transplant lymphoproliferative disorder, KSHV-associated Kaposi's sarcoma in AIDS patients, and HTLV-1-associated acute, chronic, and smoldering subtypes of adult T-cell lymphoma, respectively. Therapeutic HPV vaccine and RNA-interference-based therapies for treating HPV-associated cervical cancers also showed some encouraging results. Taken together, antiviral therapies have yielded promising results in cancer prevention and treatment. More large-scale studies are necessary to confirm the efficacy of antiviral therapy. Further investigation for more effective and convenient antiviral regimens warrants more attention. ? 2014 Springer-Verlag Berlin Heidelberg.
SDGs
Other Subjects
adefovir; alpha interferon; antiretrovirus agent; antivirus agent; arginine butyrate; arsenic trioxide; beta interferon; boceprevir; butyric acid; DNA vaccine; ganciclovir; indinavir; interferon; lamivudine; peginterferon; placebo; ribavirin; telaprevir; unclassified drug; Wart virus vaccine; zalcitabine; zidovudine; aciclovir; alpha interferon; antineoplastic agent; antisense oligonucleotide; entecavir; ganciclovir; interferon alpha plus zidovudine; peginterferon alpha; peginterferon alpha2a; pegylated interferon plus ribavirin; ribozyme; small interfering RNA; telbivudine; tenofovir; valganciclovir; zalcitabine; acquired immune deficiency syndrome; adoptive transfer; antiviral therapy; article; cancer control; cancer immunotherapy; cancer prevention; disease association; drug efficacy; drug response; Epstein Barr virus infection; hepatitis B; hepatitis C; Hodgkin disease; human; Human immunodeficiency virus infection; Human T cell leukemia virus 1; Kaposi sarcoma; merkel cell polyomavirus; Merkel cell tumor; mixed infection; nasopharynx cancer; nonhuman; papillomavirus infection; posttransplant lymphoproliferative disease; practice guideline; priority journal; RNA interference; T cell leukemia; treatment duration; treatment outcome; viral clearance; virus infection; antiviral resistance; Article; cancer incidence; cancer risk; Epstein Barr virus; Epstein Barr virus associated lymphoma; hepatitis B; Hepatitis B virus; hepatitis C; Hepatitis C virus; Human herpesvirus 8; Human immunodeficiency virus infection; Human T-lymphotropic virus 1; immunotherapy; liver cell carcinoma; lymphoma; Merkel cell polyomavirus; RNAi therapeutics; survival; uterine cervix cancer; virus load; virus replication; Wart virus; Adult; Antiviral Agents; Humans; Neoplasms; Oncogenic Viruses; Tumor Virus Infections
Publisher
Springer New York LLC
Type
journal article